Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 5;34(7):1004-1022.e8.
doi: 10.1016/j.cmet.2022.06.007.

FKBP11 rewires UPR signaling to promote glucose homeostasis in type 2 diabetes and obesity

Affiliations

FKBP11 rewires UPR signaling to promote glucose homeostasis in type 2 diabetes and obesity

Hilde Herrema et al. Cell Metab. .

Abstract

Chronic endoplasmic reticulum (ER) stress and sustained activation of unfolded protein response (UPR) signaling contribute to the development of type 2 diabetes in obesity. UPR signaling is a complex signaling pathway, which is still being explored in many different cellular processes. Here, we demonstrate that FK506-binding protein 11 (FKBP11), which is transcriptionally regulated by XBP1s, is severely reduced in the livers of obese mice. Restoring hepatic FKBP11 expression in obese mice initiates an atypical UPR signaling pathway marked by rewiring of PERK signaling toward NRF2, away from the eIF2α-ATF4 axis of the UPR. This alteration in UPR signaling establishes glucose homeostasis without changing hepatic ER stress, food consumption, or body weight. We conclude that ER stress during obesity can be beneficially rewired to promote glucose homeostasis. These findings may uncover possible new avenues in the development of novel approaches to treat diseases marked by ER stress.

Keywords: ER stress; FKBP11; NRF2; UPR signaling; glucose intolerance; insulin resistance; obesity; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests U.O. is a founder of ERX Pharmaceuticals and a member of its scientific advisory board and board of directors. ERX Pharmaceuticals does not have any relation to the work reported in this article.

Comment in

Publication types

LinkOut - more resources